Shares of aTyr Pharma, Inc. (LIFE Quick QuoteLIFE ) surged 66.97% after the company announced positive results from its phase Ib/IIa double-blind, placebo-controlled study of its lead candidate, ATYR1923.
The study was a randomized, double-blind, placebo-controlled, multiple-ascending dose clinical study in 37 patients with pulmonary sarcoidosis.
aTyr is developing ATYR1923 as a potential therapeutic for patients with severe inflammatory lung diseases. The lead indication for ATYR1923 is pulmonary sarcoidosis.
Pulmonary sarcoidosis is an inflammatory disease....More>>>